The Iranian Journal of Obstetrics, Gynecology and Infertility

The Iranian Journal of Obstetrics, Gynecology and Infertility

The frequency of chemotherapy induced amenorrhea in premenopausal patients with breast cancer in the Ayatollah Rohani hospital of Babol

Document Type : Original Article

Authors
Mohammad Ranaei 1
Mohsen Vakili Sadeghi 2
Mohammad Hossein Taghvaei 3
1 Associate professor, Department of Pathology, Clinical Research Development Unit of Rouhani Hospital, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
2 Assistant professor, Department of Hematology and Medical Oncology, Cancer Research Center, Health Research Institute, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
3 General Practitioner, Clinical Research Development Unit of Rouhani Hospital, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
10.22038/ijogi.2021.18296
Abstract
Introduction: Breast cancer is the most common cancer in women worldwide. One of the late and long-term complications of chemotherapy regimens used in the treatment of these patients is chemotherapy induced amenorrhea (CIA). Studies have shown that CIA improves prognosis in breast cancer patients with positive estrogen receptor. So, this study was performed with aim to determine the frequency of CIA in patients with breast cancer.
Methods: This retrospective descriptive-analytical study was performed on 96 premenopausal breast cancer patients aged less than 50 years old who underwent chemotherapy in Ayatollah Rohani Hospital of Babol during 2009_2015. Chemotherapy regimens include six cycles of adriamycin and cyclophosphamide (AC) per two weeks or four cycles of AC followed by four cycles of one taxane. Demographic data of the patients, date of amenorrhea and return of menstruation, chemotherapy regimen, size of tumor and number of metastatic lymph nodes were collected by researcher-made questioner and were analyzed with SPSS software (version 18) and T-test and Chi-square test.
Results: In this study, 96 patients (37.5%) had age of ≤40 years and 60 patients (62.5%) aged 40-50 years. Fifty eight patients (60.4%) experienced chemotherapy-induced amenorrhea. 44 subjects (73.3%) of patients aged 40-50 years and 14 (38%) of those aged < 40 years experienced CIA (p=0.001). CIA was 61% in AC regimen and was 59.5% in AC and taxane regimen (p=0.87).
Conclusion: CIA is common that is more common in patients older than 40 years. Addition of taxane to anthracycline-based chemotherapy regimen didn’t increase CIA.
Keywords
Amenorrhea
Breast cancer
Chemotherapy
Taxane
  1. Keihanian SH, Fotokian Z, Ghaffari F, Vahdani M, Shirinkam F, Saravi MM. Incidence of chemotherapy-induced amenorrhea in non-menopausal women with breast cancer. Journal of Mazandaran University of Medical Sciences 2009; 19(70):9-17.
  2. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics 2015; 72(2):333-8.
  3. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. InSeminars in oncology 2009; 36(3):237-249.
  4. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. The breast journal 2007; 13(4):383-91.
  5. Pourali L, Kermani AT, Ghavamnasiri MR, Khoshroo F, Hosseini S, Asadi M, et al. Incidence of chemotherapy-induced amenorrhea after adjuvant chemotherapy with taxane and anthracyclines in young patients with breast cancer. Iranian journal of cancer prevention 2013; 6(3):147.
  6. Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast cancer research and treatment 2010; 120(1):245-51.
  7. Zhou Q, Yin W, Du Y, Shen Z, Lu J. Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature. Menopause (New York, NY) 2015; 22(10):1091.
  8. Okanami Y, Ito Y, Watanabe C, Iijima K, Iwase T, Tokudome N, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast cancer 2011; 18(3):182-8.
  9. Liem GS, Mo FK, Pang E, Suen JJ, Tang NL, Lee KM, et al. Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PloS one 2015; 10(10):e0140842.
  10. Kil WJ, Do Ahn S, Shin SS, Lee SW, Choi EK, Kim JH, et al. Treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients. Breast cancer research and treatment 2006; 96(3):245-50.
  11. Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncologica 2016; 55(6):664-70.
  12. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. American journal of clinical oncology 2007; 30(2):126-32.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 24, Issue 3
May 2021
Pages 1-5